MRTNZ Investment Office · S&P 500 · The 360 Vantage
MRK · NYSE
Merck & Company, Inc. Common Stock (new)
Health Care · Biotechnology: Pharmaceutical Preparations
Reference price$128.63As of Jul 30, 2026
Street view
Analyst targets
Published sell-side aggregation—not an MRTNZ forecast.
Forward calendar
Current earnings expectations
Consensus may change until the company reports.
Dec 2026$2.74Street EPS consensus
Dec 2027$9.72Street EPS consensus
Dec 2028$11.06Street EPS consensus
Reported results
Annual financial snapshot
Fiscal period ended Dec 31, 2025.
MetricCurrentPrior
Revenue+1.3% YoY$65.01B$64.17B
Operating income$21.22B$19.91B
Net income$18.25B$17.12B
Operating cash flow$16.47B$21.47B
Capital expenditures($4.11B)($3.37B)
Current context
Related news
Company-linked articles surfaced by Nasdaq.
Evidence
Sources & method
Nasdaq quote →Nasdaq summary →Earnings forecast →Annual financials →Official S&P 500-tracking holdings →
Facts, estimates, and scenarios are kept separate. Analyst targets and EPS expectations are third-party estimates, not MRTNZ forecasts. Index weight uses the official IVV portfolio as the denominator. Illustrative research, not investment advice.